Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK3U1X)

Drug Name
ALT-803 Drug Info
Synonyms IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [1]
Bladder cancer 2C94 Phase 2 [2]
Non-hodgkin lymphoma 2B33.5 Phase 1/2 [3]
Non-small-cell lung cancer 2C25.Y Phase 1/2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
Human immunodeficiency virus infection 1C62 Phase 1 [5]
Multiple myeloma 2A83 Phase 1 [2]
Pancreatic cancer 2C10 Phase 1 [3]
Cross-matching ID
TTD Drug ID
DMK3U1X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Interleukin 15 receptor alpha (IL15RA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NKTR-255 DM7SMNJ Colorectal cancer 2B91.Z Phase 1/2 [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 15 receptor alpha (IL15RA) TTGN89I I15RA_HUMAN Agonist [6]

References

1 ClinicalTrials.gov (NCT03050216) QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02384954) ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15;73(10):3075-86.
7 Clinical pipeline report, company report or official report of Nektar Therapeutics.